SAN JOSE, Calif.--(BUSINESS WIRE)--Due to challenges in synthesis due to their structure, beta-amyloid peptides with sequences 1-44 to 1-48 have not been commercially available until now. AnaSpec, a leading provider of integrated proteomics solutions, has introduced the industry’s first commercially available beta-amyloid peptides for sequences 1-44, 1-45, 1-46, 1-47, 1-48 and 1-49.
